Capricor Therapeutics (NASDAQ:CAPR) Price Target Raised to $25.00 at Maxim Group

Capricor Therapeutics (NASDAQ:CAPR) had its target price hoisted by Maxim Group from $12.00 to $25.00 in a research note issued to investors on Wednesday morning, Benzinga reports. Maxim Group currently has a buy rating on the biotechnology company’s stock.

A number of other research firms also recently issued reports on CAPR. Cantor Fitzgerald reissued an overweight rating and set a $8.00 price target on shares of Capricor Therapeutics in a research report on Friday, September 20th. HC Wainwright restated a buy rating and issued a $40.00 price target on shares of Capricor Therapeutics in a report on Tuesday, September 24th. Finally, Oppenheimer reissued an outperform rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Capricor Therapeutics has a consensus rating of Moderate Buy and an average price target of $22.60.

Capricor Therapeutics Price Performance

Shares of NASDAQ CAPR opened at $9.95 on Wednesday. Capricor Therapeutics has a 1 year low of $2.68 and a 1 year high of $12.87. The firm has a 50-day simple moving average of $4.80 and a two-hundred day simple moving average of $5.31. The company has a market cap of $318.19 million, a P/E ratio of -11.44 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The business had revenue of $3.97 million during the quarter, compared to analysts’ expectations of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. As a group, equities research analysts expect that Capricor Therapeutics will post -1.14 EPS for the current year.

Insiders Place Their Bets

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of Capricor Therapeutics stock in a transaction that occurred on Friday, September 20th. The stock was purchased at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the acquisition, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 12.00% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Several institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new stake in shares of Capricor Therapeutics during the first quarter worth approximately $40,000. Main Street Financial Solutions LLC grew its holdings in shares of Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares during the period. Rhumbline Advisers purchased a new stake in Capricor Therapeutics in the 2nd quarter valued at about $147,000. Bank of New York Mellon Corp lifted its position in Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after buying an additional 9,040 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Capricor Therapeutics during the second quarter worth about $426,000. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.